Compare Medpace Holdings Inc (MEDP) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs ProShares Ultra QQQ ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while ProShares Ultra QQQ ETF trades at $98.43 (market cap $15.38B). The key difference: Medpace Holdings Inc and ProShares Ultra QQQ ETF are close in size by market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 4,844,085). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| MEDP | QLD | |
|---|---|---|
Market Cap | $16.82B | $15.38B |
Volume | 223,093 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $100.77 |
52-Week Low | $393.42 | $57.16 |
Typical Hold Time | 14 Days | 36 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
QLD trades at $98.43, down 1.8% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains key support at $96 with resistance at $100. Recent news highlights QLD's resilience compared to higher-leverage alternatives during market downturns, with institutional buying activity noted in recent filings.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face volatility risks from Federal Reserve policy and Nasdaq concentration. QLD's 2x leverage strategy offers a middle ground for Nasdaq-100 exposure, but requires careful risk management during market stress periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
